| scholarly article | Q13442814 |
| P2093 | author name string | Jinying Ge | |
| Xijun Wang | |||
| Zhigao Bu | |||
| Zhiyuan Wen | |||
| Minmin Zhang | |||
| Xiaofang Li | |||
| Weiye Chen | |||
| P2860 | cites work | Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses | Q24631361 |
| Ebola virus vaccines: an overview of current approaches | Q26999232 | ||
| FcgammaRIV: a novel FcR with distinct IgG subclass specificity | Q28594064 | ||
| Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. | Q30357521 | ||
| Development and application of avian influenza vaccines in China. | Q30380885 | ||
| Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. | Q30382650 | ||
| The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody | Q30450655 | ||
| Vesicular stomatitis | Q33635884 | ||
| Review of the 1997 outbreak of vesicular stomatitis in the western United States | Q33769817 | ||
| Recombinant Newcastle disease virus as a vaccine vector | Q33850246 | ||
| Oncolytic viruses: From bench to bedside with a focus on safety | Q34044071 | ||
| Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants | Q34327111 | ||
| Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza | Q34650303 | ||
| Nonsegmented negative-strand viruses as vaccine vectors | Q35139219 | ||
| Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats | Q35140435 | ||
| Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. | Q36190495 | ||
| Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response | Q36190519 | ||
| IgG2a restriction of murine antibodies elicited by viral infections | Q36352342 | ||
| Vesicular stomatitis virus Indiana glycoprotein as a T-cell-dependent and -independent antigen | Q36634104 | ||
| Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus | Q36898706 | ||
| Newcastle disease virus as a vaccine vector for humans. | Q37070421 | ||
| Structures of vesicular stomatitis virus glycoprotein: membrane fusion revisited | Q37111740 | ||
| Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors | Q37348513 | ||
| A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV. | Q37492711 | ||
| Tick vaccines: current status and future directions | Q38569829 | ||
| Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs | Q39326613 | ||
| Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response | Q39592979 | ||
| Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector | Q39877530 | ||
| More is not necessarily better: prozone-like effects in passive immunization with IgG. | Q40662584 | ||
| Immunization Against Infectious Disease | Q40883637 | ||
| Complement component 3: a new paradigm in tuberculosis vaccine | Q40895750 | ||
| Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle | Q41773463 | ||
| Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin | Q41867044 | ||
| Recombinant Newcastle disease viral vector expressing hemagglutinin or fusion of canine distemper virus is safe and immunogenic in minks | Q42149271 | ||
| Novel in-ovo chimeric recombinant Newcastle disease vaccine protects against both Newcastle disease and infectious bursal disease | Q42230168 | ||
| Epizootic vesicular stomatitis in Colorado, 1982: epidemiologic and entomologic studies | Q42991994 | ||
| Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice | Q43792197 | ||
| IFN-gamma-independent IgG2a production in mice infected with viruses and parasites | Q58846910 | ||
| Protective immunity in cattle vaccinated with a commercial scale, inactivated, bivalent vesicular stomatitis vaccine | Q73298442 | ||
| Immune responses in mice, cattle and horses to a DNA vaccine for vesicular stomatitis | Q73594817 | ||
| A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS | Q107473800 | ||
| P921 | main subject | Newcastle disease virus | Q327082 |
| vesicular stomatitis | Q11549084 | ||
| Newcastle disease | Q11903425 | ||
| P304 | page(s) | 31 | |
| P577 | publication date | 2016-02-24 | |
| P1433 | published in | Virology Journal | Q7934868 |
| P1476 | title | Protective efficacy of a recombinant Newcastle disease virus expressing glycoprotein of vesicular stomatitis virus in mice | |
| P478 | volume | 13 |
Search more.